Literature DB >> 6831348

Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal.

N D Nigro, H G Seydel, B Considine, V K Vaitkevicius, L Leichman, J J Kinzie.   

Abstract

Twenty-eight patients with squamous cell carcinoma of the anal canal were treated by preoperative radiation therapy and chemotherapy. The radiation therapy was given for 3000 rad (30 Gy) at 200 rad per day, 5 days a week, to the primary tumor with margin and to the pelvic and inguinal lymph nodes. Chemotherapy was given in the form of 5-fluorouracil infusion 1000 mg/m2 on days 1-4 of the radiation therapy and repeated on days 29-32 of the treatment regimen. Mitomycin C was given in the form of intravenous bolus for 15 mg/m2 on day 1. Surgery was done 4-6 weeks following the last day of radiation treatment. Twelve patients underwent anteroposterior resection, and seven of the 12 had no residual tumor in the surgical specimen, while one patient had microscopic tumor only. An additional 14 patients had complete clinical disappearance of their tumor, and, on excision of the scar, it was found free of microscopic cancer. Two other patients are clinically free of tumor but had no biopsy after therapy. While transient proctitis leukopenia and thrombocytopenia were moderate to severe, no serious complications were observed in these patients. Twenty-two patients are free of tumor and alive one to eight years after treatment. One patient died a cardiac death without tumor four years after surgery. Four patients, all with residual tumor in the specimen, have died of cancer. Their primary lesions were more than 7 cm in maximum diameter at initial examination. One patient died of disseminated disease with no local recurrence after abdominal perineal resection.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6831348     DOI: 10.1002/1097-0142(19830515)51:10<1826::aid-cncr2820511012>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  66 in total

1.  [Anal HPV infections].

Authors:  Felix Aigner; Friedrich Conrad; Andreas Widschwendter; Robert Zangerle; Bettina Zelger; Alfred Haidenberger; Sebastian Roka; Kurt Heim; Reinhard Höpfl; Martin Klimpfinger; Yves Marcus Rigler; Hugo Bonatti; Johann Pfeifer; Andrea Maier; Reinhard Kirnbauer; Andreas Salat
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

2.  Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal.

Authors:  Michael D Chuong; Jessica M Freilich; Sarah E Hoffe; William Fulp; Jill M Weber; Khaldoun Almhanna; William Dinwoodie; Nikhil Rao; Kenneth L Meredith; Ravi Shridhar
Journal:  Gastrointest Cancer Res       Date:  2013-03

3.  Phase II study of combination bleomycin, vincristine and high-dose methotrexate (BOM) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal.

Authors:  N Wilking; N Petrelli; L Herrera; A Mittelman
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 4.  Advances in the Management of Anal Cancer.

Authors:  Diana R Julie; Karyn A Goodman
Journal:  Curr Oncol Rep       Date:  2016-03       Impact factor: 5.075

5.  Successful treatment of anal carcinoma with Paclitaxel, Cisplatin, and radiotherapy in a patient who developed a coronary syndrome from 5-fu.

Authors:  Shalini Garg; Ross A Abrams; William T Leslie
Journal:  Gastrointest Cancer Res       Date:  2012-07

6.  Toxicity and survival of anal cancer patients treated with intensity-modulated radiation therapy.

Authors:  A Ghareeb; K Paramasevon; P Mokool; H van der Voet; M Jha
Journal:  Ann R Coll Surg Engl       Date:  2018-11-28       Impact factor: 1.891

7.  Combined chemoradiation therapy for anal cancer. A report of 56 cases.

Authors:  R Doci; R Zucali; L Bombelli; F Montalto; G Lamonica
Journal:  Ann Surg       Date:  1992-02       Impact factor: 12.969

8.  Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer.

Authors:  Alberto Alvarado-Miranda; Oscar Arrieta; Carlos Gamboa-Vignolle; David Saavedra-Perez; Rafael Morales-Barrera; Enrique Bargallo-Rocha; Juan Zinser-Sierra; Victor Perez-Sanchez; Teresa Ramirez-Ugalde; Fernando Lara-Medina
Journal:  Radiat Oncol       Date:  2009-07-11       Impact factor: 3.481

9.  Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.

Authors:  Leonard L Gunderson; Kathryn A Winter; Jaffer A Ajani; John E Pedersen; Jennifer Moughan; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher G Willett
Journal:  J Clin Oncol       Date:  2012-11-13       Impact factor: 44.544

10.  Concurrent chemoradiotherapy for squamous cell carcinoma of the anus using a shrinking field radiotherapy technique without a boost.

Authors:  A A Melcher; D Sebag-Montefiore
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.